About Us
MHG is Swiss based company with strong network of pharmaceutical relationships throughout Europe.
Our team of practitioners have combined 200+ years of experience in drug development, drug distribution, logistics and data science.
We have relationships with leading hospitals and research institutions who partner with us for clinical studies and drug development.
We have very strong experience with solutions orchestration in pharmaceutical space.
What we Do?
We work with family offices and foundations who are interested in enabling inventors of small molecules to see their inventions to market.
Often such value is trapped due to complexity of development process and market dynamics.
We orchestrate teams and groups to develop intellectual property through clinical process and enable pathways to market.
We are both patient and inventor centric - our goal is to bring valuable and effective therapies to patients. We effectively un-trap social value which can be realized Targets include but not limited to orphan diseases and repurposing for value to children and underserved demographics.
How we do it
We invest in relationships with drug researchers (inventors) who have promising intellectual property. We bring together market feedback, development expertise, project management and financial support to drive value inflections together with the inventors.
We collaborate with CROs and university research groups in win-win partnership models. By doing so we leverage the best talent and reduce the overall risks of development.
We explore novel partnerships with medical device companies who may have diagnostic capability or paradigms of behavioral change to create a novel combined therapy.
From funding perspective, we have structured models for engagement which follow industry standard approaches. Our difference is how we select partners and team members. Our philosophy is to compose focused leadership teams around specific clusters of IP and develop strong incentives towards development milestone success. We believe in sharing value which is created with the teams and investors who take risk to develop.
We are excited about the future potential to leverage data for new value creation. We are excited about potential for accelerated development leveraging Web 3.0 technologies and related business models. We have blockchain experts and leading thinkers in our advisory team.